I think on balance it's 50/50. I still think the submitted trial evidence is low quality and insufficient to satisfy the FDA for approval but they may relent in the requirement for a new trial and grant conditional approval with specific deadlines for a new trial. Overall though ignoring recommendations from the FDA is hazardous.
MSB Price at posting:
$1.18 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)